IP Group PLC Oxford Nanopore's LamPORE test gains CE-IVD mark (6442B)
October 09 2020 - 4:46AM
UK Regulatory
TIDMIPO TIDMTTM
RNS Number : 6442B
IP Group PLC
09 October 2020
FOR RELEASE ON 9 October 2020
THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED
UNDER THE MARKET ABUSE REGULATION (EU) NO.596/2014.
Portfolio company Oxford Nanopore Technologies announces LamPORE
test, for the detection of SARS-CoV-2, gains CE-IVD mark with
initial roll out in Europe and the UAE
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the
developer of intellectual property-based businesses, notes that its
portfolio company Oxford Nanopore Technologies Ltd ("Oxford
Nanopore" or "the Company") has announced that its LamPORE test is
now CE marked for in vitro diagnostic use for the detection of the
SARS-CoV-2 virus that causes COVID-19, using its GridION
device.
Oxford Nanopore noted that the LamPORE test is now in the
process of initial rollouts in the UK, Germany, Switzerland and the
United Arab Emirates. The Company previously announced that it had
partnered with the UK's Department of Health and Social Care with
an initial order of 450,000 LamPORE SARS-CoV-2 tests and the
potential to increase to millions of tests per month. Further
regulatory approvals are being pursued in other countries,
including Emergency Use Authorisation in the United States, and
with its partner G42 in the United Arab Emirates.
Oxford Nanopore's LamPORE test has been found to show a
sensitivity of 99.1% [96.9-99.9] and specificity of 99.6%
[98.0-100] after scientists from the University of Oxford's
Nuffield Department of Medicine, Public Health England Porton Down
(PHE) and the University of Sheffield, Sheffield Teaching Hospitals
NHS Foundation Trust published their evaluation. The results
indicate that LamPORE has a similar performance to RT-PCR for the
diagnosis of SARS-CoV-2 infection in symptomatic patients.
Alan Aubrey, Chief Executive of IP Group, said: "Oxford Nanopore
has made exceptional technical progress this year while playing a
critical role to help support the response to the pandemic. The
team at Oxford Nanopore has done an incredible job of bringing this
innovative testing platform to market in such a short space of
time. Oxford Nanopore is a great example of the kind of
world-changing innovation that IP Group backs and supports from the
beginning and we are delighted to see the Company go from strength
to strength."
For more information, please contact:
IP Group plc www.ipgroupplc.com
+44 (0) 20 7444 0050
Greg Smith, Chief Financial Officer +44 (0) 20 7444 0062/+44 (0)
Liz Vaughan-Adams, Communications 7979 853802
Charlotte Street Partners
David Gaffney +44 (0) 7854 609998
Andrew Wilson +44 (0) 7810 636995
Notes for editors
About IP Group
IP Group is a leading intellectual property commercialisation
company which focuses on evolving great ideas, mainly from its
partner universities, into world-changing businesses. The Group has
pioneered a unique approach to developing these ideas and the
resulting businesses by providing access to business building
expertise, capital (through its 100%-owned FCA-authorised
subsidiaries IP Capital and Parkwalk Advisors), networks,
recruitment and business support. IP Group has a strong track
record of success and its portfolio comprises holdings in
early-stage to mature businesses across life sciences and
technology. IP Group is listed on the Main Market of the London
Stock Exchange under the code IPO.
For more information, please visit our website at
www.ipgroupplc.com .
ENDS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCMLBPTMTIMMJM
(END) Dow Jones Newswires
October 09, 2020 04:46 ET (08:46 GMT)
Ip (LSE:IPO)
Historical Stock Chart
From Apr 2024 to May 2024
Ip (LSE:IPO)
Historical Stock Chart
From May 2023 to May 2024